iShares气候意识与转型MSCI美国ETF USCL 深 沪
等待开盘 03-26 09:30:00 美东时间
74.7091
+0.468
+0.63%
华盛通- 最 高74.7091
- 今 开74.88
- 成交量 20股
- 最 低 74.7091
- 昨 收 74.2413
- 总市值 21.14亿
- 52周最高 80.4002
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 58.0709
- 委 比 9.09%
- 总股本 2830.00万
- 历史最高 80.4002
- 量 比 0
- 振 幅 0.00%
- 历史最低 46.1911
- 每 手 1
- 风险率 5.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1
BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1 Sarepta Therapeutics Inc SRPT.O : SAREPTA ANNOUNCES FIRST CLINICAL DATA FROM SIRNA PIPELINE TARGETING FSHD1 AND DM1 SAREPTA THERAPEUTICS INC - SIRNA ACHIEVES HIGH MUSCLE CONCENTRATIONS WITHOUT DOSE LIMITING TOXIC
03-25 20:29
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
Austin, Texas, United States, March 24th, 2026, FinanceWire Soligenix(NAS...
03-25 00:30
BRIEF-Aro Biotherapeutics Reports Positive Phase 1B Topline Results For Abx1100, A Muscle-Targeted Gys1 Sirna, In Patients With Late-Onset Pompe Disease (Lopd)
BRIEF-Aro Biotherapeutics Reports Positive Phase 1B Topline Results For Abx1100, A Muscle-Targeted Gys1 Sirna, In Patients With Late-Onset Pompe Disease (Lopd) March 17 (Reuters) - ARO BIOTHERAPEUTICS REPORTS POSITIVE PHASE 1B TOPLINE RESULTS FOR ABX1100, A MUSCLE-TARGETED GYS1 SIRNA, IN PATIENTS WI
03-17 20:31
BRIEF-TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
BRIEF-TARA-002 Demonstrates 68% Complete Response Rate At Six Months In BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Feb 23 (Reuters) - Protara Therapeutics Inc TARA.O : TARA-002 DEMONSTRATES 68% COMPLETE RESPONSE RATE AT SIX MONTHS IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER PROTA
02-24 06:28
BRIEF-Northstrive Biosciences Signs Definitive License Agreement For Commercialization Of El-22 And El-32
BRIEF-Northstrive Biosciences Signs Definitive License Agreement For Commercialization Of El-22 And El-32 Feb 11 (Reuters) - PMGC Holdings Inc ELAB.O : NORTHSTRIVE BIOSCIENCES SIGNS DEFINITIVE LICENSE AGREEMENT FOR COMMERCIALIZATION OF EL-22 AND EL-32, A MYOSTATIN-ENGINEERED PROBIOTIC FOR MUSCLE PRE
02-11 20:46
BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint
Dec 17 (Reuters) - PFIZER: PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL & STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, & OVERALL SURVIVAL PFIZER: PATHOLOGIC COMPLETE RES...
2025-12-17 19:45
BRIEF-Anktiva® With Bcg Demonstrates 96% Survival From Bladder Cancer
Dec 16 (Reuters) - Immunitybio Inc IBRX.O: ANKTIVA® WITH BCG DEMONSTRATES 96% SURVIVAL FROM BLADDER CANCER AT THREE YEARS WITH MEDIAN SURVIVAL NOT YET REACHED IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-...
2025-12-16 22:10
BRIEF-Wave Life Sciences Announces Positive Interim Data From Phase 1 Inlight Trial Of WVE-007 For Obesity
Dec 8 (Reuters) - WAVE Life Sciences Ltd WVE.O: WAVE LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 1 INLIGHT TRIAL OF WVE-007 (INHBE) FOR OBESITY; SINGLE DOSE RESULTED IN IMPROVEMENT IN BOD...
2025-12-08 20:31
BRIEF-Relmada Gets FDA Support For Two Registrational Study Paths For NDV-01 In Non-Muscle Invasive Bladder Cancer
Nov 4 (Reuters) - Relmada Therapeutics Inc RLMD.O: RELMADA ANNOUNCES FDA FEEDBACK SUPPORTING 2 SEPARATE ACCEPTABLE REGISTRATIONAL STUDY PATHS FOR NDV-01 IN NON-MUSCLE INVASIVE BLADDER CANCER RELMADA T...
2025-11-04 20:46
COLUMN-Turbulent markets fuel LME's recovery from nickel crisis: Andy Home
By Andy Home LONDON, Oct 10 (Reuters) - Crisis? What crisis? It's hard to believe that just over three years ago the London Metal Exchange (LME) was teetering on the brink of a death spiral after its ...
2025-10-10 22:05
